Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Dare Bioscience	$2.07 -1.9%	$2.57	$1.83 ▼ $9.19	$19.05M	1.11	397,598 shs	256,463 shs
HLVX HilleVax	$2.08 +0.5%	$2.03	$1.34 ▼ $2.17	$103.79M	0.77	830,207 shs	46,260 shs
SAVA Cassava Sciences	$2.41 +5.7%	$2.14	$1.15 ▼ $33.98	$110.14M	-2.05	899,276 shs	971,565 shs
TCRX TScan Therapeutics	$1.81 +2.3%	$1.67	$1.02 ▼ $6.23	$100.17M	0.99	265,487 shs	400,820 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Dare Bioscience	+3.94%	-6.64%	-31.72%	-26.74%	-49.76%
HLVX HilleVax	+0.49%	+0.98%	-4.61%	+5.61%	+21.05%
SAVA Cassava Sciences	-1.72%	-2.56%	+5.56%	+11.22%	-90.46%
TCRX TScan Therapeutics	+5.99%	+2.31%	-7.81%	+35.11%	-69.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DARE Dare Bioscience	2.3693 of 5 stars	3.5	5.0	0.0	2.0	0.0	0.0
HLVX HilleVax	1.5801 of 5 stars	1.0	4.0	0.0	1.9	3.3	1.3
SAVA Cassava Sciences	2.0659 of 5 stars	1.0	1.0	4.7	2.0	0.0	1.3
TCRX TScan Therapeutics	3.7677 of 5 stars	3.5	5.0	0.0	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Dare Bioscience	3.00	Buy	$12.00	479.71% Upside
HLVX HilleVax	2.00	Hold	$2.00	-3.85% Downside
SAVA Cassava Sciences	2.00	Hold	$2.00	-17.01% Downside
TCRX TScan Therapeutics	3.00	Buy	$7.80	330.94% Upside

Current Analyst Ratings Breakdown

Latest DARE, HLVX, TCRX, and SAVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/12/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Dare Bioscience	$10K	1,869.21	N/A	N/A	($0.69) per share	-3.00
HLVX HilleVax	N/A	N/A	N/A	N/A	$2.95 per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A
TCRX TScan Therapeutics	$2.82M	36.32	N/A	N/A	$3.12 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	N/A	N/A	-8.14%	8/14/2025 (Estimated)
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	8/14/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$1.50	N/A	N/A	N/A	N/A	-87.72%	-72.05%	8/14/2025 (Estimated)
TCRX TScan Therapeutics	-$127.50M	-$1.09	N/A	N/A	N/A	-1,964.88%	-63.33%	-40.19%	N/A

Latest DARE, HLVX, TCRX, and SAVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	-$0.45	+$0.10	-$0.45	$0.14 million	N/A
8/14/2025	Q2 2025	HLVX HilleVax	-$0.14	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	SAVA Cassava Sciences	N/A	-$0.18	N/A	-$0.92	N/A	N/A
8/12/2025	Q2 2025	TCRX TScan Therapeutics	-$0.28	-$0.2848	-$0.0048	-$0.28	$1.31 million	$3.08 million
8/6/2025	Q2 2025	HLVX HilleVax	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Dare Bioscience	N/A	0.56	0.56
HLVX HilleVax	N/A	26.39	26.39
SAVA Cassava Sciences	N/A	9.08	9.08
TCRX TScan Therapeutics	0.18	7.06	8.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Dare Bioscience	6.70%
HLVX HilleVax	86.42%
SAVA Cassava Sciences	38.05%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
DARE Dare Bioscience	4.80%
HLVX HilleVax	24.90%
SAVA Cassava Sciences	2.40%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Dare Bioscience	30	9.03 million	8.60 million	Not Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
SAVA Cassava Sciences	30	48.31 million	47.15 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	54.13 million	Not Optionable

DARE, HLVX, TCRX, and SAVA Headlines

Recent News About These Companies

Wedbush Reaffirms Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)

August 14 at 2:15 AM | americanbankingnews.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

August 13 at 1:41 PM | marketbeat.com

TScan Therapeutics Reports Q2 2025 Financial Results

August 13 at 8:28 AM | msn.com

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

August 12 at 5:26 PM | msn.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

August 12 at 4:01 PM | zacks.com

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12 at 7:00 AM | globenewswire.com

TScan Therapeutics (TCRX) to Release Quarterly Earnings on Monday

August 10, 2025 | americanbankingnews.com

Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) Price Target at $7.80

August 6, 2025 | americanbankingnews.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

August 5, 2025 | marketbeat.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by Brokerages

August 3, 2025 | marketbeat.com

TScan Therapeutics Elects New Directors at Annual Meeting

July 27, 2025 | theglobeandmail.com

One TScan Therapeutics Insider Raised Stake By 18% In Previous Year

July 19, 2025 | finance.yahoo.com

Tscan Therapeutics Inc News (TCRX) - Investing.com

July 9, 2025 | investing.com

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

What Analysts Are Saying About TScan Therapeutics Stock

May 9, 2025 | nasdaq.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, HLVX, TCRX, and SAVA Company Descriptions

Dare Bioscience NASDAQ:DARE

$2.07 -0.04 (-1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$2.16 +0.10 (+4.59%)

As of 07:58 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

HilleVax NASDAQ:HLVX

$2.08 +0.01 (+0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.08 +0.00 (+0.19%)

As of 06:23 PM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Cassava Sciences NASDAQ:SAVA

$2.41 +0.13 (+5.70%)

Closing price 04:00 PM Eastern

Extended Trading

$2.36 -0.05 (-1.91%)

As of 08:00 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

TScan Therapeutics NASDAQ:TCRX

$1.81 +0.04 (+2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 -0.01 (-0.28%)

As of 07:25 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time